NCT02675439 - Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2016

Primary Completion Date

December 11, 2019

Study Completion Date

August 6, 2020

Conditions

Advanced/Metastatic Solid Tumors or Lymphomas

Interventions

DRUG

ADU-S100

BIOLOGICAL

ipilimumab

Trial Locations (7)

Columbia University Medical Center-Herbert Irving Pavilion, New York

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

University of Chicago Medical Center, Chicago

University of Colorado School of Medicine, Aurora

University of Utah Huntsman Cancer Institute, Salt Lake City

Dana-Farber Cancer Institute, Boston

University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston